ARWR Arrowhead Pharmaceuticals Inc.

29.12
-0.16  -1%
Previous Close 29.28
Open 29.31
Price To Book 12.29
Market Cap 2,775,164,887
Shares 95,300,992
Volume 208,719
Short Ratio
Av. Daily Volume 1,279,510

NewsSee all news

  1. Arrowhead Pharmaceuticals Presents Initial Top-Line Clinical Data and Preclinical Data on RNAi Candidates ARO-APOC3 and ARO-ANG3

    Arrowhead Pharmaceuticals Inc. (NASDAQ:ARWR) today presented initial top-line clinical data at The Global Summit on Cardiology and Heart Diseases, being held in Dubai, UAE. The data demonstrate that, in two Phase I

  2. Arrowhead Pharmaceuticals to Participate in Upcoming September 2019 Conferences

    Arrowhead Pharmaceuticals Inc. (NASDAQ:ARWR) today announced that it is scheduled to participate in the following upcoming events: Baird's 2019 Global Healthcare Conference – New York, September 4-5,

  3. Arrowhead Collaborator Janssen Begins REEF-1 Phase 2b Combination Study in Patients with Chronic Hepatitis B Infection

    - Arrowhead earns $25 million milestone payment in connection with trial initiation Arrowhead Pharmaceuticals Inc. (NASDAQ:ARWR) today announced that Janssen Pharmaceuticals, Inc., part of the Janssen Pharmaceutical

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Announced that development will be discontinued - November 29, 2016.
ARC-AAT
Alpha-1 antitrypsin deficiency (AATD)
Announced that development will be discontinued - November 29, 2016.
ARC-521
Chronic Hepititis B (HBV)
Announced that development will be discontinued - November 29, 2016.
ARC-520 injection in combination with entecavir or tenofovir
Chronic Hepititis B (HBV)
Phase 2b initiation announced August 28, 2019.
ARO-HBV / JNJ-3989
Hepatitis B (HBV)
Phase 2/3 dosing has commenced - noted August 8, 2019.
ARO-AAT
Alpha-1 Liver Disease
Phase 1 initial data presented September 16, 2019 mean maximal reductions of plasma triglycerides of 66%.
ARO-ANG3
Dyslipidemia
Phase 1 initial data presented September 16, 2019 noted mean maximal reductions of plasma triglycerides of 63%.
AROAPOC31001
Familial chylomicronemia syndrome (FCS) / Hypertriglyceridemia
Phase 2 open label trial to be initiated soon - June 27, 2019.
AROAAT2002 - Europe
AATD-associated liver disease

Latest News

  1. Arrowhead Pharmaceuticals Presents Initial Top-Line Clinical Data and Preclinical Data on RNAi Candidates ARO-APOC3 and ARO-ANG3

    Arrowhead Pharmaceuticals Inc. (NASDAQ:ARWR) today presented initial top-line clinical data at The Global Summit on Cardiology and Heart Diseases, being held in Dubai, UAE. The data demonstrate that, in two Phase I

  2. Arrowhead Pharmaceuticals to Participate in Upcoming September 2019 Conferences

    Arrowhead Pharmaceuticals Inc. (NASDAQ:ARWR) today announced that it is scheduled to participate in the following upcoming events: Baird's 2019 Global Healthcare Conference – New York, September 4-5,

  3. Arrowhead Collaborator Janssen Begins REEF-1 Phase 2b Combination Study in Patients with Chronic Hepatitis B Infection

    - Arrowhead earns $25 million milestone payment in connection with trial initiation Arrowhead Pharmaceuticals Inc. (NASDAQ:ARWR) today announced that Janssen Pharmaceuticals, Inc., part of the Janssen Pharmaceutical